Alignment: How to Know Whether Your Protocol Still Fits
Six questions establish whether a protocol still matches the person taking it, and most long-standing protocols fail at least two.
The Short Answer
A protocol can be well constructed and no longer appropriate, which is a different failure from being badly constructed. The person it was built for has changed, the problem it addressed may have resolved, and the evidence behind parts of it may have moved. Six questions establish whether it still fits, and they are worth running annually because most protocols in place for more than two years fail at least two of them.
Question One: Does Each Item Still Have a Reason
The most basic test, and the most commonly failed.
For each item, state what problem it addresses, which marker or symptom it targets, and what would indicate it is working. If you cannot answer for an item, it has stopped being a decision and become an inherited habit.
The common cases: a corrective item whose underlying problem resolved, such as vitamin D continued after status normalised and stayed normal, or berberine continued after insulin sensitivity was restored. An item added during a specific period, a training block, a stressful year, a recovery, that outlasted the period. An item whose original rationale you no longer remember.
What this does not mean. Maintenance items working by an ongoing mechanism, fibre, plant sterols, omega-3 for triglycerides, legitimately continue indefinitely, because the effect stops when they stop. The distinction is between an item still doing something and an item still being taken.
Anything failing this question goes to a removal trial, which resolves it definitively.
Question Two: Do the Markers Still Say the Same Thing
| If this changed | Reconsider |
|---|---|
| Vitamin D normalised and stable | Dose, and seasonal rather than year-round |
| Ferritin normalised | Iron, with the original cause established |
| Fasting insulin and triglycerides normalised | Corrective glycaemic items |
| hs-CRP normalised | Anti-inflammatory additions, if that was their purpose |
| ApoB still above target | Whether the approach is adequate; likely a clinical conversation |
| A marker never re-measured | Whether the item has ever been evaluated at all |
| Body composition changed substantially | Doses that scale with mass, and the whole priority order |
The last two rows are the important ones. An item added for a marker that was never re-measured has never been evaluated, which means it is being continued on faith. And a substantial change in body composition or age shifts the priority order rather than just the doses.
The row about apoB above target is the opposite failure: not an unnecessary item but an inadequate approach maintained too long. Alignment cuts both ways, and continuing a supplement approach where a clinical one is indicated is a misalignment too.
Question Three: Has the Evidence Moved
Nothing in a supplement routine prompts a re-read of the literature, which makes this the least-checked question.
The clearest historical examples: ginkgo, tested in large prevention trials and negative. Glucosamine and chondroitin, tested and largely negative with guidelines moving against routine use. B vitamins for cardiovascular prevention, negative. Vitamin E, neutral with harm signals. Beta-carotene, harmful in smokers. Each was a defensible addition before its trial reported.
What to check annually: whether anything in your stack has been the subject of a major trial, and whether guideline positions have shifted. Both are searchable in minutes for a short stack, and impossible for a long one.
The asymmetry worth noting: negative results receive far less coverage than positive ones, so a compound quietly failing a trial may not reach you. That is a reason to check rather than to wait for news.
Also in this category: dose revisions. Omega-3 dose expectations rose as trials clarified that meaningful effects need 2 g or more of EPA and DHA, and melatonin dose expectations fell as the timing mechanism became clearer.
Question Four: Is It Still Safe for You
This is the question with the highest stakes and the clearest triggers.
Any new medication changes the interaction picture. A stack safe with no medications may not be safe with an anticoagulant, an immunosuppressant, a statin or a thyroid replacement.
A new condition, particularly kidney or liver impairment, changes the handling of several compounds and can make previously reasonable items inappropriate.
Pregnancy or planning pregnancy.
Planned surgery, since several supplements affect bleeding.
Age. Kidney and liver function decline gradually, medication burden rises, and both change the calculus.
Dose creep. Whether any item has been escalated over time, which is both a safety question and a signal that the item is not addressing the actual problem.
Cumulative load. Whether the stack has grown to a size where hepatic load and interaction space are concerns in themselves.
This question should be run at every new prescription rather than annually, and it is the one where a system checking systematically outperforms memory most clearly.
Questions Five and Six
Five: does it match your current priorities? A protocol built for performance at 35 is not the right protocol for function at 65. The specific inversion that matters: in later decades, lean mass and bone preservation outrank metabolic optimisation, which means restriction-based approaches that improved markers in midlife can become net harmful. Also relevant: a protocol built for a goal you no longer have, or one that never addressed a goal you have acquired.
Six: is the foundation actually in place? This is the question that most reorders a protocol. If sleep is irregular, training is inconsistent, protein is inadequate or blood pressure is unaddressed, then the stack is operating on the smallest available variable while the largest goes unattended.
The honest check: over the last month, how many nights had a consistent wake time, how many resistance sessions happened, what was weekly aerobic volume, and when was blood pressure last measured properly. If those answers are poor, the correct protocol change is not a supplement adjustment.
That question fails more often than any of the other five, and it fails silently, because a well-maintained stack can coexist with a badly maintained foundation and the stack is the visible part.
What to Do With the Answers
Items with no current reason: removal trial, one at a time.
Items whose marker normalised: removal trial with a re-measurement, since the marker will show whether the item was maintaining it.
Items whose evidence weakened: remove, and note that this is a finding rather than a preference.
Items with a new interaction: resolve before anything else, by timing separation, dose change or removal, and involve a clinician where a prescribed medication is affected.
Priorities that shifted: reorder rather than add. Usually this means more emphasis on protein, resistance training and bone loading, and less on restriction.
A foundation not in place: stop adjusting the stack and address the foundation. This is the single highest-value response available and the least satisfying.
An inadequate approach maintained too long: escalate. Where apoB remains above target, blood pressure above threshold, or a symptom unresolved, a longer supplement trial is not the answer.
A protocol that passes all six is aligned. Most do not, and running the questions annually is what keeps the gap from widening unnoticed.
The AEONNN Perspective
Alignment is what AEONNN's continuity architecture is for: not building the best protocol once, but keeping it matched to a member as they change. These six questions are the audit, and the platform runs them rather than waiting for a member to notice a mismatch.
Two of them fail most often. The evidence question, because nothing in a supplement routine prompts a re-read of the literature and negative results receive far less coverage than positive ones. And the foundation question, because a well-maintained stack can coexist with irregular sleep, inconsistent training and unaddressed blood pressure, and the stack is the visible part.
Misalignment runs in both directions, which is worth stating. An unnecessary item continued is one failure. An inadequate approach maintained too long is another, and where apoB stays above target or blood pressure above threshold, the platform's output is escalation rather than a longer supplement trial. The Safety layer's question runs at every new prescription rather than annually, because that is where systematic checking outperforms memory most clearly.
Pillar Matrix mapping
Database Matrix layers
- Real-Time User Layer (wearable and adherence signals)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Safety Layer (DrugBank, FAERS)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
Frequently Asked
How do I know whether my protocol still fits?
Run six questions: does each item still have a reason, do the markers still say the same thing, has the evidence moved, is it still safe for you, does it match your current priorities, and is the foundation actually in place.
Which question fails most often?
Whether the foundation is in place. A well-maintained stack can coexist with irregular sleep, inconsistent training and unaddressed blood pressure, and the stack is the visible part.
Should items whose markers normalised be removed?
Corrective items, yes, with a removal trial and a re-measurement, since the marker will show whether the item was maintaining it. Maintenance items working by an ongoing mechanism legitimately continue.
How would I know the evidence changed?
By checking annually whether anything in your stack has been the subject of a major trial or a guideline shift. Negative results receive far less coverage, so this needs checking rather than waiting for news.
When should the safety question be run?
At every new prescription rather than annually, plus on a new condition, pregnancy, planned surgery, and where any item has escalated in dose over time.
What changes with age?
The priority order inverts in later decades, where lean mass and bone preservation outrank metabolic optimisation, so restriction-based approaches that improved midlife markers can become net harmful.
Can a protocol be misaligned by being too small?
Yes. An inadequate approach maintained too long is a misalignment, and where apoB stays above target or blood pressure above threshold, escalation rather than a longer supplement trial is the answer.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.